 |
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
U.S. Food and Drug Administration
Drugs that May Interact with Protease Inhibitors via CYP3A4 Metabolism -- Table VDecember 18, 1997 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. The following is a
list of medications that may potentially interact with ritonavir
therapy via cytochrome P450, specifically CYP3A4 isoenzyme
metabolism. Clinical trials measuring the magnitude of these
potential interactions have not been conducted. Additionally both
saquinavir and indinavir are metabolized via CYP3A4. The extent
of these interactions is unknown at this time. Therefore, it may
be appropriate to use therapeutic drug concentration monitoring,
and/or increased monitoring of therapeutic and adverse effects
when concomitantly administering any of the following medications
with protease inhibitors, especially for agents with narrow
therapeutic margins. Dosage reductions may be required for those
medications that are extensively metabolized by CYP3A4.
Please refer to Norvir™ product labeling information for further details regarding other potential drug interactions via CYP2D6, CYP2C9/19, glucuronidation and other pathways.
Reference: Norvir™ Prescribing Information (March 1, 1996) This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. This article was provided by U.S. Food and Drug Administration. It is a part of the publication Protease Inhibitors Backgrounder.
|
E-Mail
Printable Single-Page
Glossary
Share
